Peregrine Capital Management LLC Raises Holdings in Emergent Biosolutions Inc (EBS)

Share on StockTwits

Peregrine Capital Management LLC raised its position in Emergent Biosolutions Inc (NYSE:EBS) by 11.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,086 shares of the biopharmaceutical company’s stock after buying an additional 30,346 shares during the quarter. Peregrine Capital Management LLC owned 0.58% of Emergent Biosolutions worth $15,059,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Gideon Capital Advisors Inc. bought a new stake in shares of Emergent Biosolutions during the 4th quarter valued at $570,000. FMR LLC lifted its position in shares of Emergent Biosolutions by 44.3% during the 3rd quarter. FMR LLC now owns 419,175 shares of the biopharmaceutical company’s stock valued at $27,594,000 after acquiring an additional 128,668 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Emergent Biosolutions by 22.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 26,779 shares of the biopharmaceutical company’s stock valued at $1,763,000 after acquiring an additional 4,980 shares during the period. MetLife Investment Advisors LLC lifted its position in shares of Emergent Biosolutions by 47.0% during the 3rd quarter. MetLife Investment Advisors LLC now owns 30,154 shares of the biopharmaceutical company’s stock valued at $1,985,000 after acquiring an additional 9,642 shares during the period. Finally, TD Asset Management Inc. lifted its position in shares of Emergent Biosolutions by 620.8% during the 4th quarter. TD Asset Management Inc. now owns 69,200 shares of the biopharmaceutical company’s stock valued at $4,102,000 after acquiring an additional 59,600 shares during the period. 84.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EBS stock opened at $53.11 on Friday. The company has a quick ratio of 2.07, a current ratio of 3.10 and a debt-to-equity ratio of 0.78. Emergent Biosolutions Inc has a twelve month low of $46.93 and a twelve month high of $73.89. The firm has a market cap of $2.74 billion, a P/E ratio of 22.79, a price-to-earnings-growth ratio of 0.83 and a beta of 1.33.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.14. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The business had revenue of $270.70 million during the quarter, compared to the consensus estimate of $269.05 million. During the same period in the prior year, the company earned $0.74 EPS. Emergent Biosolutions’s revenue for the quarter was up 39.7% on a year-over-year basis. On average, research analysts expect that Emergent Biosolutions Inc will post 3.23 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on EBS shares. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research report on Thursday, January 3rd. Cantor Fitzgerald set a $75.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, January 4th. Chardan Capital set a $71.00 price objective on Emergent Biosolutions and gave the stock a “buy” rating in a research report on Friday, February 22nd. ValuEngine downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Finally, Wells Fargo & Co set a $68.00 price objective on Emergent Biosolutions and gave the stock a “hold” rating in a research report on Friday, March 1st. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $70.43.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 10,369 shares of the stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $59.65, for a total value of $618,510.85. Following the completion of the transaction, the chairman now directly owns 1,478,306 shares in the company, valued at $88,180,952.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam Havey sold 2,430 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $56.93, for a total value of $138,339.90. Following the completion of the transaction, the executive vice president now owns 32,240 shares of the company’s stock, valued at $1,835,423.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 58,132 shares of company stock valued at $3,411,113. 13.40% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Peregrine Capital Management LLC Raises Holdings in Emergent Biosolutions Inc (EBS)” was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.tickerreport.com/banking-finance/4292480/peregrine-capital-management-llc-raises-holdings-in-emergent-biosolutions-inc-ebs.html.

About Emergent Biosolutions

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

See Also: Call Option

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect PS Business Parks Inc  Will Post Quarterly Sales of $105.10 Million
Zacks: Analysts Expect PS Business Parks Inc Will Post Quarterly Sales of $105.10 Million
$7.55 Billion in Sales Expected for Medtronic PLC  This Quarter
$7.55 Billion in Sales Expected for Medtronic PLC This Quarter
MVL  Price Hits $0.0006 on Top Exchanges
MVL Price Hits $0.0006 on Top Exchanges
USA Compression Partners LP  Receives Average Recommendation of “Buy” from Brokerages
USA Compression Partners LP Receives Average Recommendation of “Buy” from Brokerages
Hush Trading Down 9.5% Over Last 7 Days
Hush Trading Down 9.5% Over Last 7 Days
EveryCoin  Price Reaches $0.0003 on Top Exchanges
EveryCoin Price Reaches $0.0003 on Top Exchanges


© 2006-2019 Ticker Report